{"id":826793,"date":"2025-03-18T08:00:03","date_gmt":"2025-03-18T12:00:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/"},"modified":"2025-03-18T08:00:03","modified_gmt":"2025-03-18T12:00:03","slug":"zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/","title":{"rendered":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death.<\/li>\n<li style=\"margin-bottom:3pt;text-align:left\">Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function.<\/li>\n<li style=\"margin-bottom:3pt;text-align:left\">Data support the potential of ZyVersa\u2019s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities.<\/li>\n<\/ul>\n<p align=\"left\">WESTON, Fla., March  18, 2025  (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate &lt;50%.<\/p>\n<p align=\"left\">\u201cThese data contribute to a growing body of scientific evidence that obesity-related heart disease can be attenuated with inflammasome inhibition, providing support for ZyVersa\u2019s Inflammasome ASC Inhibitor IC 100 as a potential therapeutic option for this obesity-related metabolic comorbidity,\u201d said Stephen C. Glover, ZyVersa\u2019s Co-founder, Chairman, CEO and President. \u201cVarious cardiovascular diseases are associated with activation of multiple inflammasomes (NLRP1, NLRP3, NLRC4, and AIM2). IC 100, which targets the ASC component of inflammasomes, inhibits all four of these inflammasomes, which we believe will lead to better control of inflammation than targeting just the NLRP3 inflammasome. Likewise, IC 100 inhibits the function of ASC Specks released from inflamed, injured cells that spread inflammation to surrounding tissues leading to development and progression of comorbidities, such as heart disease.\u201d<\/p>\n<p align=\"left\">The article published in the peer-reviewed <em>Journal of the American Heart Association <\/em>was titled <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dnf8A4Y3icBLV8E42cULbfczCtchQT5nEHV4GXk8KcHhfHaJHf8CJFoFEDUEdG5dOZ6Agu-ACCajLVFABmAM5cFAwrDJkuDlEzQP5X2aFU63OhLSbR6wsvxazYgLABxZKTL7XzEXD3aiICf053leKBejtMB1CSCcZrn0yECQ25eDfDZOlzHlH2TvDl0iL6u2qeU41eC-IKN9TmfZitURzukacujgN2bIGD_Xg_kLXRqph9pBn_KAZIgEYZMXDe1T9O2Ru-FN7a4DeghA-hCz8Hih2Yd2q_PRn6G2cXMhOM3XnY4z296bRQvZZ8_2bDQp\" rel=\"nofollow\" target=\"_blank\"><u>Impeding Nucleotide-Binding Oligomerization Domain-Like Receptor 3 Inflammasome Ameliorates Cardiac Remodeling and Dysfunction in Obesity-Associated Cardiomyopathy<\/u><\/a>. The researchers report data from studies conducted in a diet-induced obesity cardiomyopathy mouse model.<\/p>\n<p align=\"left\">\n        <strong>Key Findings<\/strong>\n      <\/p>\n<p align=\"left\">NLRP3 Inflammasome Inhibition:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:3pt\">Reduced body weight and fasting blood glucose in obese mice after 24 weeks on a high fat diet.<\/li>\n<li style=\"margin-bottom:3pt\">Reduced cardiac inflammation.<\/li>\n<li style=\"margin-bottom:3pt\">Prevented myocardial hypertrophy (enlarged heart muscle), fibrosis, and cardiac dysfunction (both systolic and diastolic), restoring maximal oxygen consumption rate.<\/li>\n<li style=\"margin-bottom:3pt\">Attenuated cardiac lipid accumulation that promotes progression of obesity-induced heart failure.<\/li>\n<\/ul>\n<p align=\"left\">The authors concluded, \u201cOur study confirms that aberrant NLRP3 inflammasome activation in cardiomyocytes worsens obesity-associated cardiomyopathy and implicates inhibition of NLRP3 inflammasome as a potent therapeutic approach for obesity cardiomyopathy.\u201d<\/p>\n<p align=\"left\">\n        <strong>About Inflammasome ASC Inhibitor IC 100<\/strong>\n      <\/p>\n<p align=\"left\">IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, and Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1\u03b2 early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1\u03b2 and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response. The lead indication for IC 100 is obesity with certain metabolic complications. To review a white paper summarizing the mechanism of action and preclinical data for IC 100, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jNiqgLhY5On5KDss7sl8lKtyw413zJWemzIQ7GOouR6NZHE02gsqL6KzifWhbhBw31go3sVsBJjEsbS5JJNGK77EKZ3GgQBuzgI4Jg0JoDALBkUAQc26QEc2qDsHK5djT6YP0qcUSBzyCrQHQMHwiWS36r193iUen9vlKgpyQKI=\" rel=\"nofollow\" target=\"_blank\"><u>Click Here<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>About ZyVersa Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"left\">ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux Mediator<sup>TM <\/sup> VAR 200. The lead indication for IC 100 is obesity and its associated metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a \u201cpipeline within a product,\u201d with potential for numerous indications. The total accessible market is over $100 billion. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uQh7Ro7Rt1t0KltZ9hnYSZSEL_9mgp1qasNWWA0WEK80nRT_pn0EHIj-0wgA1MKw6FxVR6KIekHVI0sQCcSAIjll9-1RWd8mK9tSveRKsJg=\" rel=\"nofollow\" target=\"_blank\"><u>www.zyversa.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Cautionary Statement Regarding Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"left\">Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management\u2019s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (\u201cZyVersa\u201d) uses words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cguidance,\u201d and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa\u2019s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa\u2019s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa\u2019s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa\u2019s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa\u2019s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa\u2019s product candidates; ZyVersa\u2019s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa\u2019s ability to protect its intellectual property position; and ZyVersa\u2019s estimates regarding future revenue, expenses, capital requirements and need for additional financing.<\/p>\n<p align=\"left\">New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.<\/p>\n<p align=\"left\">This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.<\/p>\n<p align=\"left\">\n        <strong>Corporate, Media, and IR Contact:<\/strong>\n      <\/p>\n<p align=\"left\">Karen Cashmere<br \/>Chief Commercial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fhhAd9oOMwcSDNl-D6N5Im8ezDDGfv0CwIS8ZdKLIvox0hrxMKsSf2oXckflHQ5EUcHlYSAgDqdFBRVHpuDpRcjPt3Y1tmf11x7IeT7lKu0=\" rel=\"nofollow\" target=\"_blank\"><u>kcashmere@zyversa.com<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3FPDJiOdqRfUBA-_WOTAj4_W3RY1CNk35uul1xxyjqo7lD6Y8ripm3QOq7V0wHvs1QcLmPQ2jX2KFhWsGdf7Nw==\" rel=\"nofollow\" target=\"_blank\"><br \/><\/a>786-251-9641<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzE3ZmI0MWUtMmJiYy00ZjAxLThjMzUtOWFkNDU1OWUwYzQyLTEyNTYwNjktMjAyNS0wMy0xOC1lbg==\/tiny\/ZyVersa-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death. Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function. Data support the potential of ZyVersa\u2019s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities. WESTON, Fla., March 18, 2025 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826793","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death. Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function. Data support the potential of ZyVersa\u2019s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities. WESTON, Fla., March 18, 2025 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition &hellip; Continue reading &quot;ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T12:00:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study\",\"datePublished\":\"2025-03-18T12:00:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/\"},\"wordCount\":1080,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/\",\"name\":\"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=\",\"datePublished\":\"2025-03-18T12:00:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/","og_locale":"en_US","og_type":"article","og_title":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - Market Newsdesk","og_description":"In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death. Data showed that NLRP3 inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function. Data support the potential of ZyVersa\u2019s Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with obesity and its associated cardiovascular comorbidities. WESTON, Fla., March 18, 2025 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published animal model data demonstrating that inflammasome inhibition &hellip; Continue reading \"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T12:00:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study","datePublished":"2025-03-18T12:00:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/"},"wordCount":1080,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/","name":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=","datePublished":"2025-03-18T12:00:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTg3NyM2ODEwMjAzIzIyNDQ1MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-highlights-data-published-in-the-journal-of-the-american-heart-association-demonstrating-inflammasome-inhibition-attenuates-obesity-associated-cardiomyopathy-in-animal-model-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826793"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}